A Randomized Active-controlled Clinical Trial to Investigate the Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet)

Sex: All

Ages: 18 Years – 85 Years

Phase: NA

Enrollment: 400

Sponsor: Seoul St. Mary's Hospital

Summary

The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure. In this study, we investigate the hemostatic effect of ClearCoajet on intraprocedural bleeding during endoscopic mucosal resection or endoscopic submucosal dissection for colorectal sessile polyps or lateral growth tumors larger than 1.5 cm. We also aim to compare the delayed bleeding and recurrence rates between the ClearCoajet group and the control group.

Eligibility Criteria

Inclusion Criteria:patients with colorectal sessile polyps or lateral growth tumors larger than 1.5 cmExclusion Criteria:Pedunculated polypPatients with coagulopathy

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05737017). StuddyBuddy aggregates publicly available trial information.